Long-term response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer: a case report

The infrequency of cases, limited guidelines, and lack of robust trials have delayed therapeutic advancements in vulvar cancer, a rare gynecologic malignancy. Here, we present a case of a 52-year-old woman with human papillomavirus–positive vulvar squamous cell carcinoma with metastases to the lung. After experiencing disease progression despite surgery and different chemotherapy combinations, smuhe enrolled in a phase I trial of relacorilant, a selective glucocorticoid receptor antagonist, plus nab-paclitaxel treatment. She experienced a remarkable response to this treatment regimen and has maintained long-term benefit for >8 years.

Authors

Institutions

Publication Details

Journal
ESMO rare cancers.
Published
2026-11-13
DOI
https://doi.org/10.1016/j.esmorc.2026.100561
Primary Topic
Genital Health and Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer: a case report

Adrian M. Jubb, Pamela N. Münster, M. Howell, K. Walker et al.
4 links
ESMO rare cancers.
Genital Health and Disease
article

Long-term response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer: a case report

Adrian M. Jubb, Pamela N. Münster, M. Howell, K. Walker, E.S. Tsang, S. Calabrese, E. Zigman, P. Lam, J. Russell, V. Monga
article en

Abstract

The infrequency of cases, limited guidelines, and lack of robust trials have delayed therapeutic advancements in vulvar cancer, a rare gynecologic malignancy. Here, we present a case of a 52-year-old woman with human papillomavirus–positive vulvar squamous cell carcinoma with metastases to the lung. After experiencing disease progression despite surgery and different chemotherapy combinations, smuhe enrolled in a phase I trial of relacorilant, a selective glucocorticoid receptor antagonist, plus nab-paclitaxel treatment. She experienced a remarkable response to this treatment regimen and has maintained long-term benefit for >8 years.

ESMO rare cancers.Vol. 8
University of California, San Francisco (US), Princess Margaret Cancer Centre (CA), Corcept Therapeutics (United States) (US)
Good health and well-being
Genital Health and Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon